Sector News

Haemonetics appoints Bill Burke CFO

August 1, 2016
Life sciences

Haemonetics Corporation today announced that William P. Burke will join the Company as Chief Financial Officer, effective August 8, 2016. In this role, he will oversee the Company’s treasury, controllership and accounting, investor relations, tax and financial planning and analysis functions.

Mr. Burke will join the Company directly from Medtronic, Inc. where he has served as Chief Integration Officer for the integration of Covidien into Medtronic since June 2015, filling the key role of principal operating officer for the integration management office. Previously, he held various Finance positions of increasing responsibility over a 20-year career with Covidien and predecessor companies, including CFO – Europe, Vice President of Corporate Strategy and Portfolio Management, and Vice President of Financial Planning and Analysis.

Christopher Simon, Haemonetics’ CEO, stated: “Bill Burke is a valuable addition to our team at an important point in time. He is a thoughtful, pragmatic leader with a strong background in all elements of strategy and finance, deep knowledge of the medical device industry and a proven ability to build strong teams that deliver peak performance amid complex change.”

Source: Haemonetics

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach